Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test
- PMID: 29101260
- DOI: 10.1136/gutjnl-2017-314753
Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test
Abstract
Background: The long-term performance of colorectal cancer (CRC) screening programmes based on a 2-year faecal immunochemical test (FIT) is still unclear.
Methods: In a sample of 50 to 69-year-olds repeatedly screened with the FIT (OC-Hemodia latex agglutination test; cut-off: 20 µg haemoglobin/g faeces), we examined: (1) the FIT positivity rate, the CRC and advanced adenoma detection rate and the FIT's positive predictive value (PPV) for advanced neoplasia, at each round of screening and (2) the cumulative CRC and advanced adenoma detection rate after five rounds of FIT.
Results: Over 12 years (2002-2014), 123 347 individuals were administered the FIT up to six times, and 781 CRCs and 4713 advanced adenomas were diagnosed. The CRC and advanced adenoma detection rates declined substantially from the first to the third (rate ratio (RR) 0.25, 95% CI 0.20 to 0.32) and second (RR 0.51, 95% CI 0.47 to 0.56) rounds, respectively, and then remained stable. The PPV for advanced neoplasia dropped by 18% in the second round (RR 0.82, 95% CI 0.77 to 0.89), with no further reduction thereafter due to a concomitant decline in the FIT positivity rate (RR first to sixth rounds: 0.56, 95% CI 0.53 to 0.60).The cumulative CRC and advanced adenoma detection rates over five consecutive rounds were 8.5‰ (95% CI 7.8 to 9.2), and 58.9‰ (95% CI 56.9 to 61.0), respectively.
Conclusions: Repeated FIT significantly reduces the burden of colorectal disease while facilitating an efficient use of colonoscopy resources. The cumulative detection rate after five rounds of FIT is similar to primary screening with colonoscopy, supporting the need to account for the cumulative sensitivity of repeated FITs when evaluating the test's efficacy.
Keywords: colonic neoplasms; colonic polyps; colonoscopy; colorectal cancer; colorectal cancer screening.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.Gut. 2020 Mar;69(3):523-530. doi: 10.1136/gutjnl-2018-318198. Epub 2019 Aug 27. Gut. 2020. PMID: 31455608
-
Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.Lancet Gastroenterol Hepatol. 2019 Feb;4(2):111-118. doi: 10.1016/S2468-1253(18)30319-4. Epub 2018 Nov 27. Lancet Gastroenterol Hepatol. 2019. PMID: 30497962
-
Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.Lancet Gastroenterol Hepatol. 2019 Aug;4(8):622-631. doi: 10.1016/S2468-1253(19)30176-1. Epub 2019 Jun 10. Lancet Gastroenterol Hepatol. 2019. PMID: 31196734
-
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2. Cochrane Database Syst Rev. 2022. PMID: 35665911 Free PMC article. Review.
-
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Gut. 2015. PMID: 26041750 Review.
Cited by
-
Cost-utility analysis of real-time artificial intelligence-assisted colonoscopy in Italy.Endosc Int Open. 2023 Nov 10;11(11):E1046-E1055. doi: 10.1055/a-2136-3428. eCollection 2023 Nov. Endosc Int Open. 2023. PMID: 37954109 Free PMC article.
-
Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.Endoscopy. 2023 Dec;55(12):1061-1069. doi: 10.1055/a-2136-6564. Epub 2023 Oct 4. Endoscopy. 2023. PMID: 37793423 Free PMC article.
-
Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.J Med Screen. 2024 Mar;31(1):8-14. doi: 10.1177/09691413231185722. Epub 2023 Jul 16. J Med Screen. 2024. PMID: 37455444 Free PMC article.
-
Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds.Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1382-1390. doi: 10.1158/1055-9965.EPI-23-0265. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37450838 Free PMC article.
-
Cost-effectiveness of Artificial Intelligence-Aided Colonoscopy for Adenoma Detection in Colon Cancer Screening.J Can Assoc Gastroenterol. 2023 Apr 7;6(3):97-105. doi: 10.1093/jcag/gwad014. eCollection 2023 Jun. J Can Assoc Gastroenterol. 2023. PMID: 37273970 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical